JPH10500005A - C型肝炎ウイルス(hcv)のns3プロテアーゼの蛋白分解活性のインビトロにおける再生方法 - Google Patents
C型肝炎ウイルス(hcv)のns3プロテアーゼの蛋白分解活性のインビトロにおける再生方法Info
- Publication number
- JPH10500005A JPH10500005A JP7522239A JP52223995A JPH10500005A JP H10500005 A JPH10500005 A JP H10500005A JP 7522239 A JP7522239 A JP 7522239A JP 52223995 A JP52223995 A JP 52223995A JP H10500005 A JPH10500005 A JP H10500005A
- Authority
- JP
- Japan
- Prior art keywords
- ns4a
- hcv
- protein
- vitro
- protease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 230000002797 proteolythic effect Effects 0.000 title claims abstract description 22
- 238000000338 in vitro Methods 0.000 title claims abstract description 20
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 title claims abstract description 16
- 241000711549 Hepacivirus C Species 0.000 title description 41
- 238000011069 regeneration method Methods 0.000 title description 2
- 230000008929 regeneration Effects 0.000 title 1
- 101710144111 Non-structural protein 3 Proteins 0.000 claims abstract description 89
- 101800001020 Non-structural protein 4A Proteins 0.000 claims abstract description 40
- 230000000694 effects Effects 0.000 claims abstract description 27
- 239000002243 precursor Substances 0.000 claims abstract description 18
- 102000004190 Enzymes Human genes 0.000 claims abstract description 10
- 108090000790 Enzymes Proteins 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 7
- 230000007017 scission Effects 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 5
- 239000011541 reaction mixture Substances 0.000 claims abstract description 5
- 238000012360 testing method Methods 0.000 claims abstract description 4
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 4
- 230000001172 regenerating effect Effects 0.000 claims abstract 6
- 230000000468 autoproteolytic effect Effects 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 108010022999 Serine Proteases Proteins 0.000 abstract description 22
- 102000012479 Serine Proteases Human genes 0.000 abstract description 22
- 239000013600 plasmid vector Substances 0.000 abstract description 5
- 230000003213 activating effect Effects 0.000 abstract description 3
- 210000004748 cultured cell Anatomy 0.000 abstract description 3
- 239000013612 plasmid Substances 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 28
- 150000001413 amino acids Chemical class 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 17
- 239000012634 fragment Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 108010076039 Polyproteins Proteins 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 101800001014 Non-structural protein 5A Proteins 0.000 description 8
- 102000035195 Peptidases Human genes 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- 239000004365 Protease Substances 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 235000019419 proteases Nutrition 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 101800001019 Non-structural protein 4B Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 230000017854 proteolysis Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 101710159910 Movement protein Proteins 0.000 description 4
- 101710144117 Non-structural protein 4 Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 101710172711 Structural protein Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 101710202200 Endolysin A Proteins 0.000 description 3
- 241000701867 Enterobacteria phage T7 Species 0.000 description 3
- 101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000006337 proteolytic cleavage Effects 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 101710122462 65 kDa protein Proteins 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101000793655 Oryza sativa subsp. japonica Calreticulin Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FQWUNUXAOHTLLG-ASDGIDEWSA-N 6-[(3s,6s,9s,12r)-3,6-dibenzyl-2,5,8,11-tetraoxo-1,4,7,10-tetrazabicyclo[10.3.0]pentadecan-9-yl]-n-hydroxyhexanamide Chemical compound C([C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)NO)C1=CC=CC=C1 FQWUNUXAOHTLLG-ASDGIDEWSA-N 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019786 Hepatitis non-A non-B Diseases 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101800001098 Serine protease NS3 Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700010756 Viral Polyproteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910001947 lithium oxide Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-M propane-1-sulfonate Chemical compound CCCS([O-])(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-M 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.HCV NS3プロテアーゼの蛋白分解活性をインビトロで再生する方法 において,NS3に含まれる配列およびNS4Aに含まれる配列の両者を反応混 合物中に使用することを特徴とする方法. 2.NS4AはNS3と1:1の比で存在させる「請求項1」に記載のHCV NS3プロテアーゼの蛋白分解活性をインビトロで再生する方法. 3.NS3およびNS4AはNS3−NS4A前駆体として反応混合物中に導 入され,その前駆体は自己蛋白分解現象により等モル量のNS3およびNS4A を産生する「請求項1または2」に記載のHCV NS3プロテアーゼの蛋白分 解活性をインビトロで再生する方法. 4.前駆体中のNS3とNS4Aの間の切断部位が突然変異されていて,その 結果,NS4AはNS3に共有結合したまま残存し,ついで上記非蛋白分解性の 前駆体からNS3の蛋白分解活性に影響しない配列を取り除くことが可能である 「請求項1〜3」のいずれかに記載のHCV NS3プロテアーゼの蛋白分解活 性をインビトロで再生する方法. 5.「請求項1〜4」に記載のNS3およびNS4A配列を含有することを特 徴とする組成物. 6.配列番号:1および配列番号:2に記載の配列またはそれらに含まれるか それらに由来する配列の蛋白質からなる「請求項5」に記載の組成物. 7.NS3に伴う酵素活性を阻害する化合物の治療目的での選択が可能な酵素 試験のセットアップのための「請求項5または6」に記載の組成物の使用. 8.NS3に伴う酵素活性を阻害する化合物の治療目的での選択が可能な酵素 試験のセットアップのため,上記説明,実施例および請求の範囲に従ってHCV NS3プロテアーゼの蛋白分解活性をインビトロで再生する方法,組成物およ びその組成物の使用.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT94A000092 | 1994-02-23 | ||
ITRM940092A IT1272179B (it) | 1994-02-23 | 1994-02-23 | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. |
PCT/IT1995/000018 WO1995022985A1 (en) | 1994-02-23 | 1995-02-14 | Method for reproducing in vitro the proteolytic activity of the ns3 protease of hepatitis c virus (hcv) |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10500005A true JPH10500005A (ja) | 1998-01-06 |
JP3280384B2 JP3280384B2 (ja) | 2002-05-13 |
Family
ID=11402272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52223995A Expired - Fee Related JP3280384B2 (ja) | 1994-02-23 | 1995-02-14 | C型肝炎ウイルス(hcv)のns3プロテアーゼの蛋白分解活性のインビトロにおける再生方法 |
Country Status (15)
Country | Link |
---|---|
US (1) | US5739002A (ja) |
EP (1) | EP0746333B1 (ja) |
JP (1) | JP3280384B2 (ja) |
AT (1) | ATE179611T1 (ja) |
AU (1) | AU691259B2 (ja) |
BR (1) | BR9506931A (ja) |
CA (1) | CA2182521C (ja) |
DE (1) | DE69509504T2 (ja) |
DK (1) | DK0746333T3 (ja) |
ES (1) | ES2132644T3 (ja) |
GR (1) | GR3030166T3 (ja) |
HK (1) | HK1010988A1 (ja) |
IT (1) | IT1272179B (ja) |
RU (1) | RU2149185C1 (ja) |
WO (1) | WO1995022985A1 (ja) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843752A (en) * | 1995-05-12 | 1998-12-01 | Schering Corporation | Soluble active hepatitis C virus protease |
US5767233A (en) * | 1995-05-12 | 1998-06-16 | Schering Corporation | Soluble cleavable substrates of the hepatitis C virus protease |
IT1278077B1 (it) * | 1995-05-25 | 1997-11-17 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal |
US5990276A (en) * | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
AU2933797A (en) * | 1996-05-10 | 1997-12-05 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
US6153579A (en) * | 1996-09-12 | 2000-11-28 | Vertex Pharmaceuticals, Incorporated | Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex |
EP1364961B1 (en) * | 1996-09-12 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained |
US5861297A (en) * | 1996-09-27 | 1999-01-19 | Merck & Co., Inc. | Detergent-free hepatitis C protease |
US6436666B1 (en) | 1996-10-17 | 2002-08-20 | Chiron Corporation | Protease regulator screening assay |
WO1998037180A2 (en) * | 1997-02-22 | 1998-08-27 | Abbott Laboratories | Hcv fusion protease and polynucleotide encoding same |
US6251583B1 (en) | 1998-04-27 | 2001-06-26 | Schering Corporation | Peptide substrates for HCV NS3 protease assays |
US6280940B1 (en) | 1998-08-05 | 2001-08-28 | Agouron Pharmaceuticals, Inc. | Reporter gene system for use in cell-based assessment of inhibitors of the Hepatitis C virus protease |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
JP2002534084A (ja) | 1999-01-08 | 2002-10-15 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎ウイルスns3プロテアーゼの修飾形 |
AU5788800A (en) * | 1999-07-07 | 2001-01-22 | Du Pont Pharmaceuticals Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
WO2001038538A1 (en) * | 1999-11-23 | 2001-05-31 | Viropharma Incorporated | Polymerase compositions and methods of use thereof |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
PL206255B1 (pl) * | 2000-07-21 | 2010-07-30 | Dendreon Corporationdendreon Corporation | Inhibitor proteazy wirusa zapalenia wątroby C, zawierająca go kompozycja farmaceutyczna i zastosowanie inhibitora do wytwarzania leku do leczenia chorób związanych z HCV oraz zastosowanie do wytwarzania kompozycji do stosowania w kombinowanej terapii |
US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
BR0112666A (pt) * | 2000-07-21 | 2003-06-10 | Schering Corp | Peptìdeos como inibidores de ns3-serina protease de vìrus da hepatite c |
AR029851A1 (es) * | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
US7022830B2 (en) | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
JP4299540B2 (ja) * | 2001-01-23 | 2009-07-22 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | C型肝炎ウイルスレプリコンおよびレプリコン増強細胞 |
JP2005504087A (ja) * | 2001-09-28 | 2005-02-10 | イデニクス(ケイマン)リミテツド | 4’が修飾されたヌクレオシドを使用するc型肝炎ウイルス治療のための方法および組成物 |
EP2172552A3 (en) | 2001-10-11 | 2010-07-21 | Merck Sharp & Dohme Corp. | Recombinant nucleic acids comprising regions of AD6 |
AU2002337840B2 (en) | 2001-10-11 | 2007-08-09 | Msd Italia S.R.L. | Hepatitis C virus vaccine |
ATE426682T1 (de) * | 2002-04-16 | 2009-04-15 | Merck & Co Inc | Hepatitis-c-virus-testsysteme |
DE602004024658D1 (de) * | 2003-02-13 | 2010-01-28 | Merck & Co Inc | Verfahren zur vermittlung von zellkulturreplikationsaktivität an unterschiedliche hepatitis-c-virus-isolate |
WO2006121468A1 (en) * | 2004-11-22 | 2006-11-16 | Genelabs Technologies, Inc. | 5-nitro-nucleoside compounds for treating viral infections |
WO2006093987A1 (en) * | 2005-02-28 | 2006-09-08 | Genelabs Technologies, Inc. | Tricyclic-nucleoside compounds for treating viral infections |
US7834145B2 (en) * | 2005-03-22 | 2010-11-16 | Merck Sharp & Dohme Corp. | HCV protease substrates |
WO2006116557A1 (en) * | 2005-04-25 | 2006-11-02 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
AU2006261132A1 (en) * | 2005-06-24 | 2006-12-28 | Genelabs Technologies, Inc. | Heteroaryl derivatives for treating viruses |
CA2627247C (en) * | 2005-10-28 | 2013-04-02 | Boehringer Ingelheim International Gmbh | Hepatitis c virus ns2/3 activity assay |
US20090203008A1 (en) | 2006-06-08 | 2009-08-13 | Ludmerer Steven W | Rapid method to determine inhibitor sensitivity of NS3/4A protease sequences cloned from clinical samples |
KR20090029827A (ko) * | 2006-07-20 | 2009-03-23 | 제네랩스 테크놀로지스, 인코포레이티드 | 폴리사이클릭 바이러스 억제제 |
US20100216161A1 (en) | 2009-02-26 | 2010-08-26 | Vertex Pharmaceuticals Incorporated | Method for identifying protease inhibitors |
EP2481807A3 (en) | 2007-03-09 | 2013-04-03 | Merck Sharp & Dohme Corp. | In vivo HCV resistance to anti-viral inhibitors |
WO2009022236A2 (en) | 2007-08-16 | 2009-02-19 | Tripep Ab | Immunogen platform |
WO2009029729A1 (en) * | 2007-08-31 | 2009-03-05 | Genelabs Technologies, Inc. | Amino tricyclic-nucleoside compounds, compositions, and methods of use |
US8324239B2 (en) | 2010-04-21 | 2012-12-04 | Novartis Ag | Furopyridine compounds and uses thereof |
MA34462B1 (fr) | 2010-07-22 | 2013-08-01 | Novartis Ag | Composes de thiophene 2,3,5- trisubstitues et leurs utilisations |
US9351989B2 (en) | 2010-12-29 | 2016-05-31 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
WO2014139587A1 (en) | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
WO2017025782A1 (en) | 2014-09-17 | 2017-02-16 | Glaxosmithkline Biologicals Sa | Improved poxviral vaccines |
US11965191B2 (en) | 2018-01-18 | 2024-04-23 | California Institute Of Technology | Programmable protein circuits in living cells |
WO2019147478A2 (en) | 2018-01-18 | 2019-08-01 | California Institute Of Technology | Programmable protein circuits in living cells |
US11453893B2 (en) | 2018-08-30 | 2022-09-27 | California Institute Of Technology | RNA-based delivery systems with levels of control |
US11542305B2 (en) | 2018-08-31 | 2023-01-03 | California Institute Of Technology | Synthetic protein circuits detecting signal transducer activity |
US11667676B2 (en) | 2019-01-10 | 2023-06-06 | California Institute Of Technology | Synthetic system for tunable thresholding of protein signals |
-
1994
- 1994-02-23 IT ITRM940092A patent/IT1272179B/it active IP Right Grant
-
1995
- 1995-02-14 RU RU96119350A patent/RU2149185C1/ru active
- 1995-02-14 DE DE69509504T patent/DE69509504T2/de not_active Expired - Lifetime
- 1995-02-14 JP JP52223995A patent/JP3280384B2/ja not_active Expired - Fee Related
- 1995-02-14 DK DK95909937T patent/DK0746333T3/da active
- 1995-02-14 EP EP95909937A patent/EP0746333B1/en not_active Expired - Lifetime
- 1995-02-14 AT AT95909937T patent/ATE179611T1/de active
- 1995-02-14 CA CA002182521A patent/CA2182521C/en not_active Expired - Fee Related
- 1995-02-14 US US08/700,356 patent/US5739002A/en not_active Expired - Lifetime
- 1995-02-14 AU AU18223/95A patent/AU691259B2/en not_active Ceased
- 1995-02-14 ES ES95909937T patent/ES2132644T3/es not_active Expired - Lifetime
- 1995-02-14 BR BR9506931A patent/BR9506931A/pt not_active Application Discontinuation
- 1995-02-14 WO PCT/IT1995/000018 patent/WO1995022985A1/en active IP Right Grant
-
1998
- 1998-11-13 HK HK98111982A patent/HK1010988A1/xx not_active IP Right Cessation
-
1999
- 1999-05-07 GR GR990401236T patent/GR3030166T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO1995022985A1 (en) | 1995-08-31 |
JP3280384B2 (ja) | 2002-05-13 |
EP0746333A1 (en) | 1996-12-11 |
DE69509504T2 (de) | 1999-09-02 |
DE69509504D1 (de) | 1999-06-10 |
EP0746333B1 (en) | 1999-05-06 |
US5739002A (en) | 1998-04-14 |
RU2149185C1 (ru) | 2000-05-20 |
IT1272179B (it) | 1997-06-16 |
HK1010988A1 (en) | 1999-07-02 |
GR3030166T3 (en) | 1999-08-31 |
ATE179611T1 (de) | 1999-05-15 |
CA2182521C (en) | 1999-07-06 |
ITRM940092A0 (it) | 1994-02-23 |
BR9506931A (pt) | 1997-09-09 |
ES2132644T3 (es) | 1999-08-16 |
CA2182521A1 (en) | 1995-08-31 |
AU691259B2 (en) | 1998-05-14 |
ITRM940092A1 (it) | 1995-08-23 |
DK0746333T3 (da) | 1999-11-01 |
AU1822395A (en) | 1995-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10500005A (ja) | C型肝炎ウイルス(hcv)のns3プロテアーゼの蛋白分解活性のインビトロにおける再生方法 | |
Banerjee et al. | Specific interaction of hepatitis C virus protease/helicase NS3 with the 3′-terminal sequences of viral positive-and negative-strand RNA | |
Lackner et al. | Temporal modulation of an autoprotease is crucial for replication and pathogenicity of an RNA virus | |
Bartenschlager et al. | Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions | |
Behrens et al. | Identification and properties of the RNA‐dependent RNA polymerase of hepatitis C virus. | |
Oliver Koch et al. | Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A, and NS4B | |
Grassmann et al. | Assignment of the multifunctional NS3 protein of bovine viral diarrhea virus during RNA replication: an in vivo and in vitro study | |
You et al. | A novel in vitro replication system for Dengue virus: initiation of RNA synthesis at the 3′-end of exogenous viral RNA templates requires 5′-and 3′-terminal complementary sequence motifs of the viral RNA | |
Chambers et al. | Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. | |
Failla et al. | Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins | |
Santolini et al. | Biosynthesis and biochemical properties of the hepatitis C virus core protein | |
Santolini et al. | The NS2 protein of hepatitis C virus is a transmembrane polypeptide | |
EP0856051B1 (en) | Novel 3' terminal sequence of hepatitis c virus genome and diagnostic and therapeutic uses thereof | |
Preugschat et al. | Processing of nonstructural proteins NS4A and NS4B of dengue 2 virus in vitro and in vivo | |
JP3310298B2 (ja) | Hcv ns3プロテアーゼのタンパク質分解活性を有するポリぺプチドを製造し、精製し、分析する方法 | |
Lee et al. | Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells | |
Sun et al. | Specific inhibition of bovine viral diarrhea virus replicase | |
Shoji et al. | Proteolytic activity of NS3 serine proteinase of hepatitis C virus efficiently expressed in Escherichia coli | |
Bukhtiyarova et al. | Inhibition of the bovine viral diarrhoea virus NS3 serine protease by a boron-modified peptidyl mimetic of its natural substrate | |
Xiao et al. | Specific interaction between the classical swine fever virus NS5B protein and the viral genome | |
Zhang et al. | Role of protein conformation in the processing of dengue virus type 2 nonstructural polyprotein precursor | |
WO1999055366A1 (en) | Chimeras of hepatitis c virus and bovine viral diarrhea virus | |
NZ529037A (en) | Method for replicating the hepatitis C virus | |
Kashiwagi et al. | Kinetic analysis of C-terminally truncated RNA-dependent RNA polymerase of hepatitis C virus | |
Ye et al. | Two cis-acting elements in negative RNA strand of hepatitis C virus involved in synthesis of positive RNA strand in vitro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090222 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100222 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110222 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120222 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130222 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130222 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140222 Year of fee payment: 12 |
|
LAPS | Cancellation because of no payment of annual fees |